Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

The Cannigma

OCTOBER 11, 2021

The majority of people who use the cannabinoid cannabigerol (CBG) for medical reasons find it to be helpful or very helpful in treating a variety of health conditions, according to the findings of a recent survey. No clinical trial was used in the compilation of the study. Why is CBG ‘the mother of all cannabinoids?’.

Conditions 132

Conditions Clinical Trials Chronic Pain Cannabinoids 132

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. & Notice of 2021 Final Results.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Canna Care Docs

OCTOBER 3, 2023

Alleviating Symptoms with Cannabinoids As more states legalize medical cannabis, many researchers and clinicians are studying the efficacy of cannabinoids like THC and CBD for alleviating these symptoms. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

MMJ Recs

DECEMBER 28, 2023

Chronic Pain Relief with Medical Marijuana: How Cannabinoids Ease Discomfort Chronic pain is a pervasive issue affecting millions worldwide, and traditional pain medications may not always offer satisfactory relief. CBD, a non-psychoactive cannabinoid, has gained attention for its anti-anxiety effects.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

The Cannigma

DECEMBER 14, 2021

Hexahydrocannabinol (HHC), which was patented in the late 1940s as a “therapeutic substance having marihuana activity,” is a cannabinoid that’s growing in popularity and availability. Hydrogenation of THC isomers such as delta-9-THC or delta-8-THC results in the formation of hexahydrocannabinol (HHC), a hydrogenated cannabinoid.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

Cannabis Law Report

MARCH 18, 2020

has created a new internal division focused on research and development of minor cannabinoids. “The launch of CW Labs formalizes our reach into the science, efficacy and safety of hemp plant compounds,” said Deanie Elsner, CEO of Charlotte’s Web in a press release. Charlotte’s Web Holdings, Inc. Source: [link].

Clinical Trials 59

Clinical Trials Research and Development Terpenes Hemp 59

The Cannigma

FEBRUARY 2, 2021

“Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” lead investigator Professor Carsten Buhmann of the University Medical Center Hamburg-Eppendorf explained in a statement.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Otherside Farms

JANUARY 25, 2019

Scientists hope to perform human trials in the near future. Researchers at the University of Nottingham conducted a meta-analysis of previous studies, reports the Nottingham Post, concluding that cannabinoids could reduce the severity of stroke as well as improve neurological outcomes.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. Following the execution of this work, cbdMD Therapeutics will perform the requisite toxicological studies with Ion Tox, a leading in vitro toxicology and ADME-PK testing company, to support the safety of the cannabinoids of interest. CHARLOTTE, N.C.–(BUSINESS

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

JANUARY 19, 2022

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Del Morgan & Co.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Medicinal Marijuana Association

FEBRUARY 11, 2024

The anti-inflammatory properties of certain cannabinoids in cannabis could also play a role in protecting retinal cells from damage associated with the condition. Studies have shown that cannabinoids, the active compounds in cannabis, may help decrease intraocular pressure by facilitating better fluid drainage from the eye.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Veriheal

APRIL 11, 2022

We could potentially develop north of 11,000 drugs that are cannabinoid-based. In particular, of all the components contained in the cannabis plant— including cannabinoids , terpenes , and flavonoids — the cannabis compound tetrahydrocannabinol (THC) has proven to harbor medicinal benefits when used in specific formulations.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

MMJ Recs

NOVEMBER 30, 2023

Studies have indicated that certain cannabinoids found in cannabis, particularly CBD, may have anticonvulsant properties. While anecdotal evidence and individual success stories have sparked interest in using MMJ for seizure control, scientific research plays a crucial role in establishing its safety and efficacy.

Epilepsy 105

Epilepsy Treatment Patients Strains 105

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Date and Time: Tuesday, October 19 th at 5:00 PM ET. Poster Number: INFO37.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Veriheal

JANUARY 5, 2023

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety. Senate approval.

Clinical Trials 82

Clinical Trials Safety Consumption CBD 82

MedicalJane

MAY 21, 2020

Researchers at The University of New Mexico (UNM) have conducted a series of recent studies testing the effectiveness and safety of consuming cannabis, but this is the first study they have conducted measuring the therapeutic potential of hemp oil with low THC levels. Hemp” is defined in the Act as “the plant Cannabis sativa L.

Oil 100

Oil Hemp Extraction Clinical Trials 100

The Joint Blog

JANUARY 23, 2020

.” For this study, “The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted.” One isolated study indicates some potential efficacy for an oral cannabinoid /terpene combination in ADHD.

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

CannaMD

SEPTEMBER 28, 2020

However, there is a tradeoff between effectiveness and safety. These represent the two most often studied cannabinoids overall, and sleep research is no different. Both cannabinoids have been studied separately for their abilities. This begs the question: Are there any remedies for coronasomnia? Is there a more natural remedy?

Sleep 72

Sleep Clinical Trials Patients THC 72

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Del Morgan & Co.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

Cannabis Law Report

JUNE 4, 2021

We support the Hemp Roundtable’s statements on psychoactive hemp and that it should be regulated separately from hemp, CBD, CBG and other non-psychoactive or non-intoxicating cannabinoids. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

SEPTEMBER 20, 2021

The products leverage pharmaceutical technology to maximize performance and safety. CB4 products are formulated based on the latest medical evidence and come in convenient dosage forms that deliver effective levels of cannabinoids. Opticann medical cannabis products merge cannabis medicine with modern medicine.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JULY 1, 2022

Because of this variability in the plant, and because of a lack of standard methods–like chemical analyses of cannabinoids or terpenes–has led to inconsistent scientific results. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66